|Year : 2011 | Volume
| Issue : 3 | Page : 167-172
The RP-HPLC method for simultaneous estimation of esomeprazole and naproxen in binary combination
Deepak Kumar Jain1, Nitesh Jain2, Rita Charde2, Nilesh Jain3
1 Truba Institute of Pharmacy, Karond Gandhi Nagar Bypass Road, Bhopal, India
2 Nri Institute of Pharmacy, 2, Sajjan Singh Nagar, Bhopal, India
3 Sagar Institute of Research and Technology-Pharmacy, Bypass Road, Bhopal 462 038, Madhya Pradesh, India
|Date of Web Publication||29-Nov-2011|
Deepak Kumar Jain
Truba Institute of Pharmacy, Karond Gandhi Nagar, Bypass Road, Bhopal, Madhya Pradesh 462 036
| Abstract|| |
Objective: A simple, precise, reliable, rapid, sensitive and validated RP-HPLC method has been developed to determine esomeprazole magnesium trihydrate (ESO) and naproxen (NAP) in synthetic mixture form. Materials and Methods: Chromatographic separation achieved isocratically on Phenomenex, Luna C18 column (5 μm, 150mm x 4.60mm) and acetonitrile: phosphate buffer (pH 7.0) in the ratio of 50:50 (v/v) as the mobile phase, at a flow rate of 0.5 ml/min. Detection was carried out at 300 nm. The retention times for NAP and ESO was found to be 2.67 ±0.014 and 5.65 ±0.09 min respectively. Parameters such as linearity, precision, accuracy, recovery, specificity and ruggedness are studied as reported in the ICH guidelines. Results: The method was linear in the concentration range of 50-250 μg/ml for NAP and 2-10 μg/ml for ESO with correlation coefficient of 0.999 and 0.998 respectively. The mean recoveries obtained for NAP and ESO were 100.01% and 97.76 % respectively and RSD was less than 2. The correlation coefficients for all components are close to 1. Conclusions: Developed method was found to be accurate, precise, selective and rapid for simultaneous estimation of NAP and ESO.
Keywords: Esomeprazole magnesium trihydrate, naproxen, RP-HPLC, validation
|How to cite this article:|
Jain DK, Jain N, Charde R, Jain N. The RP-HPLC method for simultaneous estimation of esomeprazole and naproxen in binary combination. Pharm Methods 2011;2:167-72
|How to cite this URL:|
Jain DK, Jain N, Charde R, Jain N. The RP-HPLC method for simultaneous estimation of esomeprazole and naproxen in binary combination. Pharm Methods [serial online] 2011 [cited 2013 May 25];2:167-72. Available from: http://www.phmethods.org/text.asp?2011/2/3/167/90356
| Introduction|| |
Esomeprazole magnesium trihydrate (ESO), bis(5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl] sulfinyl]-1-H-benzimidazole-1-yl)magnesium trihydrate [Figure 1]a, is a compound that inhibits gastric acid secretion. ESO is cost-effective in the treatment of gastric oesophageal reflux diseases. ESO is the S-isomer of omeprazole, the first single optical isomer proton pump inhibitor, generally provides better acid control than current racemic proton pump inhibitors and has a favorable pharmacokinetic profile relative to omeprazole. Several methods have been employed for the estimation of ESO alone and combination with other drugs such as UV and RP-HPLC methods. ,,,,,,,, Naproxen (NAP) is chemically, (S)-6-methoxy-α-methyl-2-naphthaleneacetic acid [Figure 1]b is a non-steroidal anti-inflammatory drug (NSAID) commonly used for the reduction of moderate to severe pain, fever, inflammation, and stiffness. It works by inhibiting both the COX-1 and COX-2 enzymes. Like other NSAIDs, NAP is capable of producing disturbances in the gastrointestinal tract. Several chromatographic methods have been reported for determination of NAP in raw material,  tablets, ,, plasma, ,,,,, urine, ,,,, plasma and urine,  serum,  intestinal perfusion samples,  and pharmaceutical preparations.  There are no pharmacokinetic drug interactions between NAP and ESO. The NAP/ESO tablet is bioequivalent to EC naproxen, and as expected, the bioavailability of non-EC esomeprazole from the NAP/ESO tablet is lower than the EC esomeprazole formulation.  According to the information collected from the literature, there is no reported method for simultaneous determination of ESO and NAP as The US Food and Drug Administration (FDA) has recently approved a fixed-dose tablet combination of delayed-release enteric-coated NAP and immediate-release ESO magnesium (Vimovo: AstraZeneca and Pozen, Inc). The tablet is available in the US market not in India. In the present work, we are therefore focused on to achieve the optimum chromatographic conditions for the simultaneous determination of ESO and NAP in a synthetic mixture. The developed method could be applied to quality control of the tablet dosage form whenever it available in Indian market. We are using the same excipients which are used by the manufacturer in tablet formulation. To access the reproducibility and wide applicability of the developed method, it was validated as per ICH guidelines,  which is mandatory also.
|Figure 1: Chemical structures of (a) esomeprazole magnesium trihydrate and (b) naproxen|
Click here to view
| Materials and Methods|| |
Liquid chromatographic Shimadzu (LC-20AT) system was manufactured by Shimadzu Science park drive Pasteur, Singapur Science Park, Gapore 118227, comprising of a manual injector, double reciprocating plunger pump LC-20ATVp for constant flow and constant pressure delivery and Photodiode array detector SPD-M20A connected to software LC solution, (Version-1.23SP1) for controlling the instrumentation as well as processing the data generated, was purchased from SpincoBiotech Pvt. Ltd., No. 3 Sector-II Shanti Nikatan Colony, Gautam Nagar, Bhopal 462023. Weighing was done on a Digital Micro Balance (CX-265) manufactured by Citizen Scale (I) Pvt. Ltd. and pH of buffer was maintained by using a Systronics pH meter.
Chemicals and reagents
Analytically pure sample of ESO was a generous gift from Glenmark Pharma Ltd., Baddi, and NAP was an obtained from Aurbindo Pharma Ltd., Hyderabad. Potassium dihydrogen phosphate, disodium hydrogen phosphate, and acetonitrile (HPLC Grade) were purchased from E. Merck Ltd. Worli, Mumbai, India. The 0.45 μm nylon filters were purchased from Advanced Micro Devices Pvt. Ltd., Chandigadh, India. All excipients used were of pharmaceutical grade. Triple distilled water was generated in house.
The isocratic mobile phase consisted of acetonitrile-phosphate buffer (pH 7.0) in the ratio of (50:50v/v), flowing through the column at a constant flow rate of 0.5 ml/min. A Phenomenex, Luna C 18 column (5 μm, 150 × 4.60 mm 2 ) was used as the stationary phase. By considering the chromatographic parameter, sensitivity and selectivity of the method for two drugs, 300 nm was selected as the detection wavelength for UV-PDA detector. The HPLC system was operated at a room temperature of 25°C.
Standard stock solution
Standard stock solutions were prepared by dissolving separately 100 mg of each drug in 100 ml of diluent which was a mixture of acetonitrile and phosphate buffer in the ratio of 50:50 (pH 7.0) to get a concentration of 1000 μg/ml.
Working standard solution
Working standard solutions were prepared by taking dilutions ranging from 50 to 250, 2 to 10 μg/ml for NAP and ESO, respectively.
A synthetic mixture was prepared by taking powdered equivalent to 500 mg NAP and 20 mg ESO, and the other tablet excipent such as carnauba wax, colloidal silicon dioxide, croscarmellose sodium, iron oxide yellow, glyceryl monostearate, hypromellose, iron oxide black, magnesium stearate, methylparaben, polysorbate 80, polydextrose, polyethylene glycol, povidone, propylene glycol, propylparaben, titanium dioxide, and triethyl citrate, which are very close to the composition of tablet formulation in 100 ml diluents and then sonicated for 15 min and filtered through Whatman paper no. 41. Then different concentrations of solution were prepared by a serial dilution technique as per standard and each dilution was analyzed.
| Results and Discussion|| |
The mobile phase was chosen after several trials with methanol, isopropyl alcohol, acetonitrile, water, and buffer solutions in various proportions and at different pH values. A mobile phase consisting of acetonitrile/phosphate buffer (50:50, v/v, pH 7.0) was selected to achieve maximum separation and sensitivity. Flow rates between 0.5 and 1.5 min were studied. A flow rate of 0.5 ml/min gave an optimal signal-to-noise ratio with a reasonable separation time. Using a reversed-phase C18 column, the retention times for NAP and ESO were observed to be 2.67 ± 0.014 and 5.65 ± 0.09 min, respectively. Total time of analysis was less than 6 min. The maximum absorption of NAP and ESO together as detected at 300 nm, and this wavelength was chosen for the analysis [Figure 2].
|Figure 2: Chromatograms of NAP (200 μg/ml) and ESO (8 μg/ml) reference substances|
Click here to view
System suitability parameters such as number of theoretical plates, HETP, and peak tailing are determined. The results obtained are shown in [Table 1]. The number of theoretical plates for ESO and NAP were 2948 and 1614, respectively.
The calibration curve was linear over the concentration range of 2-10 μg/ml for ESO and 50-250 μg/ml for NAP. The linearity was represented by a linear regression equation as follows:
Y (NAP)= 6066.07conc. + 17036.93 (r2 = 0.999),
Y (ESO)= 34935.04conc. + 2042.686 (r2 = 0.998)
where Y isthe area under curve and r2 is the correlation coefficient.
Method accuracy was performed by adding known amounts of NAP and ESO to the preanalysed synthetic mixture solution and then comparing the added concentration with the found concentration. Three levels of solutions were made which correspond to 80%, 100%, and 120% of the nominal analytical concentration (4 μg/ml for ESO and 100 μg/ml for NAP). Each level was made in triplicate [Table 2]. The mean percentage recoveries obtained for NAP and ESO were 100.01% and 97.76%, respectively, and RSD was less than 2.
Five dilutions in three replicates were analyzed in the same day for repeatability and results were found within acceptable limits (RSD < 2) as shown in [Table 3].
Five dilutions in three replicates were analyzed on two different days and by two analysts for day-to-day and analyst-to-analyst variations, and results were found within acceptable limits (RSD < 2) as shown in [Table 3].
As per ICH norms, small, but deliberate variations, by altering the pH or concentration of the mobile phase were made to check the method's capacity to remain unaffected. The change was made in the ratio of mobile phase, instead of acetonitrile:phosphate buffer (pH 7.0) (50:50 v/v), acetonitrile:phosphate buffer (pH 7.0) (55:45 v/v) was used as a mobile phase. Results of analysis were summarized in [Table 3].
Stability of sample solution
The sample solution injected after 12 h do not show any appreciable change. Results are shown in [Table 4].
Specificity and selectivity
Commonly used excipients were spiked in to a preweighed quantity of drugs. The chromatogram was taken by appropriate dilution and the quantities of drug were determined. The specificity of the HPLC method is illustrated in [Figure 3]. Where complete separation of NAP (naproxen) and ESO (esomeprazole) in presence of tablet excipients.
|Figure 3: Chromatograms of NAP (150 μg/ml) and ESO (6 μg/ml) in a synthetic mixture|
Click here to view
Synthetic mixture analysis
The concentration of ESO and NAP in the synthetic mixture was found to be 100% and 98.77%, respectively. The low values of % coefficient of variation indicate that the method is precise and accurate in [Table 5].
| Conclusion|| |
A simple precise, reliable, rapid, sensitive, and accurate reverse phase HPLC method has been developed for the simultaneous determination of ESO and NAP. The developed method is suitable for the identification and quantification of binary combination of ESO and NAP. A high percentage of recovery and the run time of less than six minutes allow its application for the routine determination of ESO and NAP in the tablet dosage form.
| References|| |
|1.||Andersson T, Hassan-Alin M, Hasselgren G, Rohss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacol 2001;40:411-26. |
|2.||Scott LJ, Dunn CJ, Mallarkey G, Sharpe M. Esomeprazole- a review of its use in the management of acid-related disorders. Drugs 2002;62:1503-38. |
|3.||Hultman I, Stenhoff H, Liljeblad M. Determination of esomeprazole and its two main metabolites in human, rat and dog plasma by liquid chromatography with tandem mass spectrometry. J Chromatogr B 2007;848:317-22. |
|4.||Johnson DA, Roach AC, Carlsson AS, Karlsson AA, Behr DE. Stability of esomeprazole capsule contents after in vitro suspension in common soft foods and beverages. Pharmacotherapy 2003;23:731-4. |
|5.||Li XQ, Anderson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821-7. |
|6.||Shetty R, Subramanian G, Kumar RA, Pandey S, Udupa N. Estimation of esomeprazole in human plasma by reverse phase high performance liquid chromatography. Indian Drugs 2005;42:158-61. |
|7.||Magesh AR, Vijayalakshmi R, Satyavati D, Sravanthi Devi G, Dhanaraju MD. Validated spectrophotometric estimation of esomeprazole using hydrotrophic solubilisation technique. Orie J Chem 2010;26:1191-3. |
|8.||Onal A, Oztunc A. Development and validation of high performance liquid chromatographic method for the determination of esomeprazole in tablets. J Food Drug Anal 2006;14:12-8. |
|9.||Prabu SL, Shirwaikar A, Shirwaikar A, Kumar CD, Joseph A, Kumar R. Simultaneous estimation of esomeprazole and domperidone by UV spectrophotometric method. Indian J Pharm Sci 2008;70:128-31. |
|10.||Patel BH, Suhagia BN, Patel MM, Patel JR. Determination of pantoprazole, rabeprazole, esomeprazole, domperidone and itopride in pharmaceutical products by reverse phase liquid chromatography using single mobile phase. Chromatographia 2007;65:743-8. |
|11.||Zanitti L, Ferretti R, Gallinella B, Torre FL, Sanna ML, Mosca A, et al. Direct HPLC enantioseparation of omeprazole and its chiral impurities: Application to the determination of enantiomeric purity of esomeprazole magnesium trihydrate. J Pharm Biomed Anal 2010;52:665-71. |
|12.||Ekpe A, Tong JH, Rodriguez L. High-performance liquid chromatographic method development and validation for the simultaneous quantitation of naproxen sodium and pseudoephedrine hydrochloride impurities. J Chromatogr Sci 2001;39:81-6. |
|13.||Dinc E, Ozdemir A, Aksoy H, Ustundag O, Baleanu D. Chemometric determination of naproxen sodium and pseudoephedrine hydrochloride in tablets by HPLC. Chem Pharm Bull 2006;54:415-21. |
|14.||Monser L, Darghouth F. Simultaneous determination of naproxen and related compounds by HPLC using porous graphitic carbon column. J Pharm Biomed Anal 2003;32:1087-92. |
|15.||Damiani P, Bearzotti M, Miguel A. Cabezon spectrofluorometric determination of naproxen in tablets. J Pharm Biomed Anal 2002;29:229-38. |
|16.||Tashtoush BM, Al-Taani BM. HPLC determination of naproxen in plasma. Pharmazie 2003;58:614-5. |
|17.||Nielsen-Kudsk F. HPLC-determination of some anti-inflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. Acta Pharmacol Toxicol 1980;47:267-73. |
|18.||Phillips TM, Wellner EF. Measurement of naproxen in human plasma by chip-based immunoaffinity capillary electrophoresis. Biomed Chromatogr 2006;20:662-7. |
|19.||Sun Y, Takaba K, Kido H, Nakashima MN, Nakashima K. Simultaneous determination of arylpropionic acidic nonsteroidal anti-inflammatory drugs in pharmaceutical formulations and human plasma by HPLC with UV detection. J Pharm Biomed Anal 2003;30:1611-9. |
|20.||Sakaguchia Y, Yoshidaa H, Hayamaa T, Yoshitakea M, Itoyamaa M, Todorokia K, et al. Fluorous derivatization and fluorous-phase separation for fluorometric determination of naproxen and felbinac in human plasma. J Pharm Biomed Anal 2011;55:176-80. |
|21.||Paul W, Elsinghorsta C, Kinziga M, Rodamera M, Holzgrabeb U, Sorgela F. An LC-MS/MS procedure for the quantification of naproxen in human plasma: Development, validation, comparison with other methods, and application to a pharmacokinetic study. J Chromatogr B 2011;879:1686-96. |
|22.||Mikami E, Goto T, Ohno T, Matsumoto H, Nishida M. Simultaneous analysis of naproxen, nabumetone and its major metabolite 6-methoxy-2-naphthylacetic acid in pharmaceuticals and human urine by HPLC. J Pharm Biomed Anal 2000;23:917-25. |
|23.||Sidelmann UV, Bjørnsdottir I, Shockcor JP, Hansen SH, Lindon JC, Nicholson JK. Directly coupled HPLC-NMR and HPLC-MS approaches for the rapid characterisation of drug metabolites in urine: Application to the human metabolism of naproxen. J Pharm Biomed Anal 2001;24:569-79. |
|24.||Aresta A, Palmisano F, Zambonin CG. Determination of naproxen in human urine by solid-phase microextraction coupled to liquid chromatograph. J Pharm Biomed Anal 2005;39:643-7. |
|25.||Sun Y, Zhang Z, Xi Z, Shi Z. Determination of naproxen in human urine by high-performance liquid chromatography with direct electrogenerated chemiluminescence detection. Talanta 2009;79:676-80. |
|26.||Mortensen RW, Corcoran O, Cornett C, Sidelmann UG, Troke J, Lindon JC, et al. LC-1H NMR used for determination of the elution order of S-naproxen glucuronide isomers in two isocratic reversed-phase LC-systems. J Pharm Biomed Anal 2001;24:477-85. |
|27.||Karida T, Avgerinos A, Malamataris S. Extractionless HPLC method for the determination of naproxen in human plasma and urine. Anal Lett 1993;26:2341-8. |
|28.||Damiani PC, Borraccetti MD, Olivieri AC. Direct and simultaneous spectrofluorometric determination of naproxen and salicylate in human serum assisted by chemometric analysis Analytica Chimica Acta 2002;471:87-96. |
|29.||Zakeri-Milani P, Barzegar-Jalali M, Tajerzadeh H, Azarmi Y, Valizadeh H. Simultaneous determination of naproxen, ketoprofen and phenol red in samples from rat intestinal permeability studies: HPLC method development and validation. J Pharm Biomed Anal 2005;39:624-30. |
|30.||Hsu Y, Liou Y, Lee J, Chen C, Wu A. Assay of naproxen by highperformance liquid chromatography and identification of its photoproducts by LC-ESI MS. Biomed Chromatogr 2006;27:787-93. |
|31.||Wang-Smith L, Fort J, Zhang Y, Sostek M. Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium. J Clin Pharmacol 2011 [In Press]. |
|32.||Code Q2 (R1) -Text on Validation of Analytical Procedures: Text and Methodology Current Step 4 version, 2005, ICH Harmonised Tripartite Guideline. |
[Figure 1], [Figure 2], [Figure 3]
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5]